From: Homozygous CDKN2A/B deletions in low- and high-grade glioma: a meta-analysis of individual patient data and predictive values of p16 immunohistochemistry testing
Metric
Sensitivity
Specificity
PPV
NPV
5% cut-off
89.6% ± 5.8%
91.3% ± 3.7%
82.6% ± 6.9%
95.0% ± 2.9%
1% cut-off
71.2% ± 7.1%
71.7% ± 5.7%
62.4% ± 7.1%
79.1% ± 5.4%
Complete absence as cut-off
77.2% ± 9.2%
80.0% ± 4.9%
54.5% ± 9.2%
91.9% ± 3.6%